Summary

A registered US patent agent and an accomplished drug hunter in pharmaceutical research. Specialized in modern organic synthesis and medicinal chemistry of the central nervous system, oncology and infectious diseases. Experienced working with patent attorneys, researchers, and inventors engaged in the preparation of original patent applications and reports relating to matters of intellectual property. Developed leadership skills in matrix organizations and partnered collaborations. Contributed to a number of projects that have entered advanced drug development. Credits also include inventorship and authorship on about fifty patents, publications, and presentations.

Professional Research Experience

Technology Specialist – Axis Intellectual Capital (2014 – present)

Responses to Official Office Actions, amendments and arguments.

Patentability and prior art searches.

Patent landscape reports.

Freedom to operate analysis.

Drafting of original claims and specifications.

Preparing PCT applications for filing; docketing; quotations; invoicing.

Recruiting and management of professional staff, CAD specialists, and translation teams.

Localization and implementation of computer aided translation systems (Trados).

Marketing and collaborating with clients and external associates.

Investigator – Novartis Institute for Tropical Diseases (2012 – 2014)

Phenotypic screening of blood and liver stage malaria inhibitors.

Library building, Field analysis (Torch), and triaging in collaboration with GVK Biosciences.

Analysis of structure-activity relationships and Spotfire data analysis.

Hit to lead generation, project progression flowcharts.

Senior Scientist – Selvita Life Science Solutions (2010 – 2012)

Co-inventor of novel 5HT-6 nootropics and PIM-1 kinase inhibitors.

X-ray structure and ligand based in-silico design of novel inhibitors (Maestro).

In-silico lead-like screening (Ro3), synthesis of hit-to-lead libraries, and lead optimization (Ro5).

Preparation of research proposals, patent applications, and project summaries.

Co-team leader in collaboration with Orion Pharmaceuticals.

Scientific Consultant – J&B Wax LLC (2009)

Scale-up and analytical analysis of commercial reagents.

Distinguished Research Fellow – Neurogen Corporation (1991 – 2008)

Project team leader for internal and partnered R&D programs.

Optimized and advanced drug candidates into development.

Developed process synthesis and synthesized bulk active ingredients.

Improved DMPK profile for selected lead compounds.

Designed and identified biologically active hits for a number of different CNS projects.

Promoted multiple times for achievements and roles as lab head and project coordinator.

Education and Distinctions

2016 US Patent Agent – Registration No. 74,633.

1990 Postdoctoral Fellow, NSERC Fellow, Yale University, New Haven CT 06520,

Advisor: Prof. Samuel J. Danishefsky.

1988 Ph.D. with Honors in Organic Chemistry, Xerox Fellow, McGill University, Montreal QC H3A 2T6,

Advisor: Prof. T.H. Chan.

1984 B.Sc. with Honors in Co-op Chemistry, University of Waterloo, Waterloo ON N2L 3G1,

Advisor: Prof. Victor A. Snieckus.

1980 Associate degree in Health Sciences, Vanier College, Montreal QC H4L 3X9.

1978 Diploma, Marymount Comprehensive High School, Montreal QC H3W 2G9.

Selected Patents, Publications and Presentations

1.Czardybon, Wojciech; Brozozka, Krzysztof; Galezowski, Michal; Windak, Renata; Milik, Mariusz; Wadzka, Magdalena; Guzik, Pawel; Wincza, Ewelina, Prokop, Marta; Wiklik, Katarzyna; Sabiniarz, Aleksandra; Cholody, Wieslaw Marek; Horvath, Raymond. Novel Benzimidazole Derivatives as Kinase Inhibitors. PCT Int. Appl. (2014), WO 201-***-****.

2.Ge, Ping; Horvath, Raymond F.; Zhang, Lu Yan; Yamaguchi, Yasuchika; Kaiser, Bernd; Zhang, Xuechun; Zhang, Suoming; Zhao, He; John, Stanly; Moorcroft, Neil; Shutske, Greg. Preparation of heteroaryl fused pyridines, pyrazines, and pyrimidines as CRF-1 receptor ligands. PCT Int. Appl. (2005), WO 200-***-****.

3.Charles-Henry Fabritius; Ullamari Pesonen; Josef Messinger; Raymond Horvath; Harri Salo; Michał Gałęzowski; Mariusz Galek; Klaudia Stefanska; Joanna Szeremeta-Spisak; Marta Olszak-Płachta; Anna Buda; Justyna Adamczyk; Marcin Krol; Peteris Prusis; Magdalena Sieprawska-Lupa; Maciej Mikulski; Katja Kuokkanen; Hugh Chapman; Radosław Obuchowicz; Timo Korjamo; Niina Jalava, 1-Sulfonyl-6-Piperazinyl-7-Azaindoles as potent and pseudo-selective 5-HT6 receptor antagonists, Bioorg. Med. Chem. Lett., in press, (2016).

4.Kevin J. Hodgetts; Ping Ge; Taeyoung Yoon; Stephane De Lombaert; Robbin Brodbeck; Michael Gulianello; Andrzej Kieltyka; Raymond F. Horvath; John H. Kehne; James E. Krause; George D. Maynard; Diane Hoffman; Younglim Lee; Laurence Fung; Dario Doller, Discovery of N -(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4- trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): An orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist, J. Med. Chem., 54(12), 4187-4206, (2011).

5.R.F. Horvath, J. Kehne, D. Hoffman, R. Brodbeck, L. Fung, Y. Yamaguchi, Topology II CRF1 Receptor Antagonists, 230th American Chemical Society National Meeting, Washington, D.C., Invited Lecture, Abstract No. 886070, August 28 to September 1, 2005.

6.Bruce Baron, John Kehne, Ray Horvath, Greg Shutske, Richard Knapp, Lawrence Fung, Robbin Brodbeck, Raisa Nagorny, Andrzej Kieltyka, Shane Coverdale, Ping Ge, and James Krause, Biochemical Characterization of a Novel CRF1 Receptor Antagonist, Fifth International Symposium on Peptide Receptors: from Gene to Therapy, Montréal, Canada, Poster No. P16, July 31 to August 4, 2004.

Contact this candidate